HBIO: Harvard Bioscience Company Total Sales

Harvard Bioscience is implementing ESG principles by reducing its carbon footprint and resource consumption in the production of medical technology. Corporate sales clearly demonstrate revenue dynamics, where 0.09 determines the current level of this parameter. Business efficiency is supported by outsourced manufacturing and logistics, while the brand's impeccable reputation among global laboratories guarantees stable demand for Harvard Bioscience products.

Harvard Bioscience, Inc. (HBIO) - Company Sales from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Harvard Bioscience, Inc. (HBIO)

- market value and analyst target forecast:

Market Chart harvardbioscience.com|HBIO - Consensus Target

- market capitalization information:

Market Value Harvard Bioscience, Inc.|HBIO - Total Company Value

- book capitalization indicators:

Accounting Value of a Share Harvard Bioscience|HBIO - Company Net Assets|Market Capitalization to Book Value Ratio harvardbioscience.com|HBIO - Aggregate Company Assets

- company liabilities and liquidity data:

Total Debt to Equity Ratio Harvard Bioscience|HBIO - Long-Term Debt to Capital|Current Liabilities to Capital Harvard Bioscience Inc.|HBIO - Company Debts|Debt to Book Value Ratio Harvard Bioscience, Inc.|HBIO - Company Long-Term Liabilities|Amount of Current Liabilities Harvard Bioscience|Interim Coverage Ratio harvardbioscience.com

- earnings and valuation multiples indicators:

HBIO - Net Profit|Expected Net Income Harvard Bioscience|HBIO - P/E Multiple|Forward P/E Multiple harvardbioscience.com|HBIO - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Harvard Bioscience, Inc.|HBIO - Operating profit before deduction of amortization|Earnings per share for the last twelve months Harvard Bioscience|HBIO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth harvardbioscience.com|HBIO - Earnings per share growth in current year|Expected earnings per share trend next year Harvard Bioscience

- issuer revenue and sales details:

HBIO - Revenue and Sales Volume|Company Revenue Forecast Harvard Bioscience Inc.|HBIO - Market Cap to Revenue|Forward Price to Sales Harvard Bioscience, Inc.

Comprehensive company analysis:harvardbioscience.com HBIO

Signature product of Harvard Bioscience, Inc.

Searching for fundamentally resilient assets requires separating short-term market noise from actual operational activity. This metric captures daily trading inflows, allowing for the determination of the statistical norm of demand and eliminating the risk of overpaying for one-off spikes. For Harvard Bioscience (HBIO), this analysis confirms the effectiveness of Jim Green's strategy to refresh the product portfolio. By assessing the company's sales revenue, an investor can verify the stability of long-term margin optimization.

Competing companies